Fig. 3: The LXRα agonist T0901317 limits TGFβ-induced myofibroblast differentiation in CAFs.
From: LXRα limits TGFβ-dependent hepatocellular carcinoma associated fibroblast differentiation

AKH12, AKH14 and AKH38 CAFs were treated in complete medium for 74 h; TGFβ1 (5 ng/ml) was administered with or without LXR agonist (5 μM T0901317). a Expression of the indicated proteins was determined by immunoblotting. Experiments were performed in biological duplicates (nb = 2). An arrow marks the correct protein band and a star a non-specific protein recognized by the LXRα antibody. Molecular size markers are indicated in kDa. b F-actin (red) and α-SMA (green) microfilaments and DAPI (blue) in CAFs, after 48 h of the indicated treatments. Bars represent 10 µm. Experiments were performed in biological triplicates (nb = 3)